Trademark Overview
On Wednesday, October 9, 2024, a trademark application was filed for ALLO CHASSIS with the United States Patent and Trademark Office. The USPTO has given the ALLO CHASSIS trademark a serial number of 79413326. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Thursday, December 26, 2024. This trademark is owned by Celyntra Therapeutics SA. The ALLO CHASSIS trademark is filed in the Chemical Products, Pharmaceutical Products, Treatment & Processing of Materials Services, and Computer & Software Services & Scientific Services categories with the following description:
Custom manufacturing of iPS derived cells, and iPS derived cell therapy and manufacturing processes for others, including manufacturing in GMP-based facilities; custom manufacture of therapeutic cells, medicines, cell therapies and gene edited cell therapies for others, including manufacturing in GMP-based facilities; custom manufacture of cellular therapies, including manufacturing in GMP-based facilities; manufacturing of cell lines (modified cells with specific genetic edits) for use in generating other cells.
Modified cells, in particular genetically modified iPS (induced pluripotent stem) cells or differentiated cells derived therefrom, for medical or veterinary use; cell cultures and cell culture systems, and cryopreserved pluripotent stem cells for medical or veterinary use; genetically modified iPS (induced pluripotent stem) cells for use in generating other cells for therapeutic purposes; cell cultures and cell culture systems, and cryopreserved genetically modified pluripotent stem cells for sub cultivation of cells.
Modified cells, in particular genetically modified iPS (induced pluripotent stem) cells and differentiated cells derived therefrom, for research or scientific purposes; cell cultures, cell culture systems and cryopreserved genetically modified iPS cells for scientific and industrial research purposes; cell cultures, and cryopreserved cells iPS cells other than for medical or veterinary use; compositions and materials for scientific use, including cell culture agents for use in the biotechnology industry and cell material for use in combination with human cells, including genetically modified iPS or differentiated stem cells.
Research and testing of cell-based products, in particular therapeutic products; research, optimization and testing of cell production processes; laboratory research in the field of biotechnology using genetically modified iPS (induced pluripotent stem) cells or differentiated cells derived therefrom; Scientific research, design and development of scientific cell culture, cell therapy or gene edited cell therapy; Scientific research, design and development of cell culture, cell therapy or gene edited cell therapy, manufacturing systems and manufacturing processes for others; platform as a service [Paas] in the field of cell therapy, and cell therapy development; providing temporary use of a technological platform for the manufacturing of cell-based therapies, including technology, processes, and data analytics capabilities for process optimization and quality control.
